Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Humacyte is a clinical-stage biotechnology company developing acellular human tissue-engineered vessels (HTEVs) for vascular repair and replacement. The company's lead product, the Human Acellular Vessel (HAV), is being evaluated for vascular trauma, arteriovenous access for dialysis, and peripheral arterial disease. With zero revenue and $100M+ annual cash burn, the stock trades on clinical trial milestones, regulatory progress, and capital runway visibility.
Pre-revenue biotech developing proprietary biofabrication platform to produce off-the-shelf vascular grafts from human smooth muscle cells. Revenue model will be product sales to hospitals/surgical centers at premium pricing versus synthetic alternatives, justified by reduced infection rates and improved patency. Competitive advantage lies in acellular technology eliminating rejection risk without immunosuppression, and potential for multiple indications from single manufacturing platform. Pricing power depends on demonstrating superior clinical outcomes in Phase 3 trials and securing reimbursement codes.
Clinical trial data readouts for vascular trauma (V007 study) and AV access (HUMANITY study) - primary endpoints on patency and safety
FDA regulatory milestones including Biologics License Application (BLA) submission timing and approval decisions
Capital raises and financing announcements - dilution risk given negative cash flow and limited runway
Partnership or licensing deals with larger medical device/pharma companies for commercialization or geographic expansion
Manufacturing scale-up progress and production capacity announcements for commercial readiness
Binary regulatory risk - BLA approval failure would be catastrophic given single-platform dependency and limited pipeline diversity
Reimbursement uncertainty - even with FDA approval, CMS and private payer coverage decisions will determine commercial viability and pricing power
Manufacturing complexity and scale-up risk - biofabrication process requires 6-8 week production cycles with quality control challenges
Long-term safety data requirements may extend commercialization timeline beyond current cash runway
Synthetic graft manufacturers (Gore-Tex, Dacron) have established relationships and lower costs despite inferior clinical profiles
Other tissue-engineered vascular graft developers including university research programs and well-funded competitors
Alternative AV access technologies including catheter-based solutions that avoid surgical implantation
Severe liquidity risk - current cash position supports operations into late 2026/early 2027 based on burn rate, requiring near-term financing
Dilution risk from equity raises at depressed valuations given 71% stock decline over past year
Negative equity position and negative book value create accounting complexities and limit debt financing options
No revenue generation to offset cash burn creates binary outcome dependency on clinical/regulatory success
low - Clinical trial timelines and regulatory processes are largely insulated from economic cycles. However, capital markets access for financing is highly sensitive to risk appetite and biotech sector sentiment. Hospital capital budgets for new technologies can be affected during severe recessions, potentially impacting post-approval adoption rates.
High sensitivity through multiple channels: (1) Rising rates compress biotech valuations as future cash flows are discounted more heavily - particularly acute for pre-revenue companies with 5+ year monetization timelines. (2) Higher rates increase cost of capital for future financings and reduce attractiveness of dilutive equity raises. (3) Rates affect institutional investor allocation to high-risk growth assets. With negative cash flow and financing needs, rising rate environment is materially negative for valuation multiples.
Minimal direct credit exposure as company has limited debt and operates primarily on equity capital. However, tightening credit conditions reduce availability of venture debt or other non-dilutive financing alternatives, forcing greater reliance on equity markets. Broader credit stress can also reduce M&A activity and partnership opportunities with strategic acquirers.
growth - High-risk, high-reward biotech investors and specialized healthcare funds willing to accept binary outcomes. Attracts momentum traders around clinical catalysts and regulatory milestones. Not suitable for value or income investors given negative cash flow, no dividends, and speculative nature. Requires long time horizon (3-5 years minimum) and tolerance for 50%+ drawdowns.
high - Stock exhibits extreme volatility with 71% decline over past year and frequent 10-20% single-day moves on clinical or regulatory news. Beta likely exceeds 2.0 relative to broader market. Volatility driven by binary event risk, low float, limited institutional ownership, and illiquidity. Options market typically prices high implied volatility around known catalyst dates.
